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A B S T R A C T
Background
Traumatic brain injury (TBI) is a leading cause of death and disability. Intracranial bleeding is a common complication of TBI, and
intracranial bleeding can develop or worsen after hospital admission. Haemostatic drugs may reduce the occurrence or size of intracranial
bleeds and consequently lower the morbidity and mortality associated with TBI.
Objectives
To assess the effects of haemostatic drugs on mortality, disability and thrombotic complications in patients with traumatic brain injury.
Search methods
We searched the electronic databases: Cochrane Injuries Group Specialised Register (3 February 2009), CENTRAL (The Cochrane
Library 2009, Issue 1), MEDLINE (1950 to Week 3 2009), PubMed (searched 3 February 2009 (last 180 days)), EMBASE (1980 to
Week 4 2009), CINAHL (1982 to January 2009), ISI Web of Science: Science Citation Index Expanded (SCI-EXPANDED) (1970
to January 2009), ISI Web of Science: Conference Proceedings Citation Index - Science (CPCI-S) (1990 to January 2009).
Selection criteria
We included published and unpublished randomised controlled trials comparing haemostatic drugs (antifibrinolytics: aprotinin, tranex-
amic acid (TXA), aminocaproic acid or recombined activated factor VIIa (rFVIIa)) with placebo, no treatment, or other treatment in
patients with acute traumatic brain injury.
Data collection and analysis
Two review authors independently examined all electronic records, and extracted the data.We judged that therewas clinical heterogeneity
between trials so we did not attempt to pool the results of the included trials. The results are reported separately.
Main results
We included two trials. One was a post-hoc analysis of 30 TBI patients from a randomised controlled trial of rFVIIa in blunt trauma
patients. The risk ratio for mortality at 30 days was 0.64 (95% CI 0.25 to 1.63) for rFVIIa compared to placebo. This result should be
considered with caution as the subgroup analysis was not pre-specified for the trial. The other trial evaluated the effect of rFVIIa in 97
TBI patients with evidence of intracerebral bleeding in a computed tomography (CT) scan. The corresponding risk ratio for mortality
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at the last follow up was 1.08 (95% CI 0.44 to 2.68). The quality of the reporting of both trials was poor so it was difficult to assess
the risk of bias.
Authors’ conclusions
There is no reliable evidence from randomised controlled trials to support the effectiveness of haemostatic drugs in reducing mortality
or disability in patients with TBI. New randomised controlled trials assessing the effects of haemostatic drugs in TBI patients should
be conducted. These trials should be large enough to detect clinically plausible treatment effects.
P L A I N L A N G U A G E S U M M A R Y
Haemostatic drugs for traumatic brain injury
Injury (also called trauma) is a leading cause of death for children and young adults. Traumatic brain injury, such as from a blow to the
head, is a frequent cause of death for patients with trauma who survive to reach hospital. Approximately half of patients with traumatic
brain injury develop bleeding into the brain within the first 48 hours of hospital admission. If bleeding occurs, accumulating blood
within the skull can put pressure on the brain and this may be fatal or result in serious long-term disability for the patient. Therefore,
drugs that promote the production of clots or reduce the destruction of existing clots (known as haemostatic drugs) might reduce the
bleeding into the brain after an injury and thereby reduce the risk of death or disability.
We searched for randomised clinical trials looking at the effectiveness of haemostatic drugs for reducing mortality and disability in
patients with traumatic brain injury. We found two studies that evaluated the effects of a type of haemostatic drug called recombined
activated factor VII. We reviewed the data presented in the reports of these trials. Both trials were too small to confirm or refute any
plausible clinical effect, so we were unable to reach any conclusions regarding the effectiveness of haemostatic drugs for traumatic brain
injury patients. More trials are needed to answer this question. Future trials should be large enough to detect plausible and important
clinical effects.
B A C K G R O U N D
Description of the condition
Traumatic brain injury is one of the main causes of death in pa-
tients with injuries, and is a leading cause of death and disabil-
ity in young people (Ghajar 2000). Every year approximately 1.5
million people die and at least 10 million people are killed or
hospitalised because of a traumatic brain injury (Langlois 2006).
The incidence, fatality and disability rates are higher in low- and
middle- income countries than in high income countries (Hyder
2007).
Althoughmuch of the damage to the brain occurs at the time of the
injury, secondary brain damage due to ongoing intracranial bleed-
ing and brain swelling is an important and potentially avoidable
cause of morbidity and mortality. Intracranial bleeding is a com-
mon complication of traumatic brain injury. In the CRASH trial,
which included patients with mild, moderate and severe traumatic
brain injury, 56% of trial participants had at least one intracranial
bleed that could have been epidural, subdural, subarachnoid or
intra-parenchymal (CRASH Trial).
There is evidence that intracranial bleeding can develop or worsen
after hospital admission. Prospective observational studies have
shown that traumatic intracranial haemorrhage expansion occurs
in up to 51% of patients with traumatic brain injury during the
first 24 to 48 hours after hospital admission (Narayan 2008). Prog-
nostic studies have shown that intracranial haemorrhage is associ-
ated with increasedmortality and disability six months after injury
(Maas 2007; Perel 2008). Intracranial bleeding exerts significant
pressure on brain tissue (Bullock 2006), and prompt neurosurgi-
cal intervention is an important part of the therapeutic approach.
However, not all intracranial haemorrhages can be controlled by
surgical intervention and there is interest in pharmacological ap-
proaches that use haemostatic drugs to reduce the occurrence or
size of intracranial bleeds (Ceylan 1992;Mandera 1999;Holcomb
2004).
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Description of the intervention
Haemostatic drugs have the potential to reduce bleeding by in-
fluencing the coagulation cascade. In the haemostatic process, co-
agulation occurs rapidly to build a tight net of fibrin at the site
of the damaged vessel. At the same time, the fibrinolytic system
removes fibrin deposits that could cause permanent occlusion of
blood vessels once vascular repair has taken place (Prentice 1980).
Thus, the coagulation and fibrinolytic systems are in a state of
dynamic balance that maintains an intact vascular system.
The treatments that have been most extensively evaluated as
haemostatic drugs include antifibrinolytics and pro-coagulant
drugs such as recombinant activated factor VII (rFVIIa) (
Mannucci 2007). Antifibrinolytic drugs maintain the stability of
blood clots, whereas pro-coagulant drugs act directly on the coag-
ulation cascade (Holcomb 2004).
The pro-coagulant rFVIIa acts locally at the site of tissue injury.
It is believed that it binds to exposed tissue factor and generates
thrombin, which activates the platelets. The activated platelet sur-
face forms a template on which recombinant factor VIIa can di-
rectly or indirectly mediate further activation of coagulation, re-
sulting in the generation of more thrombin and, ultimately, in the
conversion of fibrinogen to fibrin.
Antifibrinolytic agents suppress fibrinolysis, thereby reducing ex-
cessive or recurrent bleeding. Antifibrinolytics can be divided into
lysine analogues (tranexamic acid (TXA) and aminocaproic acid)
and plasmin inhibitors (aprotinin). The former impairs endoge-
nous fibrinolysis by blocking lysine binding sites on plasminogen
molecules. In contrast, aprotinin directly inhibits the fibrinolytic
enzyme plasmin, plasma and tissue kallikrein, trypsin and acti-
vated coagulation factor XII.
How the intervention might work
Haemostatic drugs have been used to prevent or reduce blood loss
and the need for blood transfusion.
For example, antifibrinolytic drugs are widely used in general
surgery to reduce bleeding and the need for transfusions (Slaughter
1997). A systematic review of the use of antifibrinolytic agents in
surgical patients identified 211 randomised controlled trials that
included 20,781 participants (Henry 2007). The results showed
that TXA reduced the risk of blood transfusion by 39% (risk ratio
(RR) 0.61, 95%confidence interval (CI) 0.54 to 0.69), while apro-
tinin lowered the risk by 34% (RR 0.66, 95% CI 0.61 to 0.71).
Antifibrinolytic agents also reduced the need for blood transfusion
and reoperation due to bleeding. There was a trend toward a de-
creased risk of death in patients treated with aprotinin (RR 0.90,
95% CI 0.67 to 1.20) and TXA (RR 0.60, 95% CI 0.32 to 1.12)
but this was not statistically significant. There was no evidence of
an increased risk of thrombotic events with either treatment.
The effects of haemostatic drugs in non-traumatic intracranial
bleeding have also been evaluated. A systematic review of ran-
domised controlled trials of antifibrinolytic drugs in patients
with aneurysmal subarachnoid haemorrhage showed that antifib-
rinolytic drugs reduced the rate of re-bleeding by approximately
40% but, because of the associated increase in cerebral ischaemia,
there was no overall benefit (Roos 2003). However, the length of
treatment in these trials was six weeks. It is possible that a shorter
treatment periodmight prevent re-bleedingwithout increasing the
risk of ischaemia. The systematic review was conducted in 2003.
Since then, a randomised controlled trial of early administration
of a short course (three days) of TXA in patients with aneurysmal
subarachnoid haemorrhage has found that TXA reduced the oc-
currence of re-bleeding from 10.8% to 2.4%, with no evidence of
increased side effects (Astrup 2006).
A systematic review of haemostatic drugs in primary intracerebral
haemorrhage (non-traumatic) found four phase II trials and re-
ported that haemostatic drugs reduced the risk of death and de-
pendence measured on the modified Rankin Scale (RR 0.79, 95%
CI 0.67 to 0.93) and the Glasgow Outcome Scale (RR 0.90, 95%
CI 0.81 to 1.01) (You 2006). A recent clinical trial, which was not
included in that systematic review, showed that activated factor
VIIa reduced intracerebral haemorrhage expansion but did not
improve the survival or functional outcomes of patients (Mayer
2008).
Why it is important to do this review
If haemostatic agents reduce intracranial bleeding in patients with
traumatic brain injury, they could substantially reduce the extent of
secondary brain damage and subsequently lower themortality and
morbidity rates associated with brain injury. Given the number of
cases of traumatic brain injury that occur each year, even a modest
reduction in the risk of unfavourable outcomes could have major
public health implications.
O B J E C T I V E S
To assess the effects of haemostatic drugs on mortality, disability
and thrombotic complications in patients with traumatic brain
injury.
M E T H O D S
Criteria for considering studies for this review
Types of studies
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We included published and unpublished randomised controlled
trials comparing haemostatic drugs with placebo, no treatment,
or other treatment in patients with acute traumatic brain injury.
Comparisons between different types of haemostatic drugs were
also to be included.
Types of participants
Any patient with traumatic brain injury.
Types of interventions
Any of the systemic haemostatic drugs listed below compared with
placebo, no treatment, or another haemostatic drug. For studies
in which different doses of the intervention were compared with
placebo, the intervention groups were combined and compared
with the control group. For the purpose of this review, we consid-
ered the following haemostatic drugs.
• Antifibrinolytics: aprotinin, tranexamic acid (TXA),
aminocaproic acid.
• Activated factor VIIa.
Types of outcome measures
Primary outcomes
1. Mortality
2. Disability (Glasgow Outcome Scale (GOS), Disability
Rating Scale (DRS), or other measure of neurological function)
3. Thrombotic complications: deep venous thrombosis
(DVT), pulmonary embolism (PE), stroke, and myocardial
infarction (MI)
Secondary outcomes
1. Volume of intracranial bleeding
2. Brain ischaemic lesions
3. Need for neurosurgical operation or reoperation
4. Renal failure
Search methods for identification of studies
The searches were not restricted by date, language, or publication
status.
Electronic searches
We searched the following electronic databases:
• Cochrane Injuries Group Specialised Register (searched 3
February 2009),
• CENTRAL (The Cochrane Library 2009, Issue 1),
• MEDLINE (1950 to Week 3 2009),
• PubMed (searched 3 February 2009 (last 180 days)),
• EMBASE (1980 to Week 4 2009),
• CINAHL (1982 to January 2009),
• ISI Web of Science: Science Citation Index Expanded (SCI-
EXPANDED) (1970 to January 2009),
• ISI Web of Science: Conference Proceedings Citation Index
- Science (CPCI-S) (1990 to January 2009).
The full search strategies can be found in Appendix 1.
Searching other resources
We searched the Internet for relevant information and conference
abstracts. We also sought other potentially relevant published, un-
published, or ongoing studies by:
1. checking the reference lists of relevant papers and literature
reviews,
2. communicating with relevant trial authors,
3. contacting the manufacturers of relevant drugs.
Data collection and analysis
Selection of studies
Two review authors (PP and IR) independently examined all elec-
tronic records and their abstracts to establish eligibility. They de-
cided on whether or not to acquire the full report and, in cases of
uncertainty, obtained the full report. We planned to resolve any
disagreements through discussion and consultation with a third
review author. Any duplicate trials were planned to be examined
individually to verify that they presented unique sets of data. If we
were unsure about whether a study should be included, because
additional information was necessary, we allocated the study to the
list of those awaiting assessment and contacted the study authors
for clarification. The reasons for excluding studies are described
in the ’Characteristics of excluded studies’ table.
Data extraction and management
Two review authors (PP and IR) extracted the data from the in-
cluded studies. We extracted data on the study methods, partici-
pants, interventions, and outcomes. We extracted data so that an
intention-to-treat analysis could be performed. For binary out-
comes, we determined the number of participants experiencing
the outcome of interest in each group. For continuous outcomes,
we used the mean change from baseline at final assessment, to-
gether with the number of participants and standard deviation for
each group.
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Assessment of risk of bias in included studies
Two review authors (PP and IR) evaluated the risk of bias of the
included studies with respect to six domains: sequence generation,
allocation concealment, blinding, incomplete outcome data, se-
lective outcome reporting, and other sources of bias. The risk of
bias in each domain was rated as high risk, low risk, and unclear.
Any disagreement between raters was resolved by consensus.
Measures of treatment effect
For dichotomous data, we calculated the risk ratio (RR) and 95%
CI.We calculated themean difference (MD) and 95%CI for con-
tinuous outcomes that were measured on the same scale, otherwise
we planned to calculate the standardised mean difference.
Dealing with missing data
We attempted to contact study authors to obtain any missing
information.
Assessment of heterogeneity
We planned to examine the participants, interventions, and out-
comes of the trials for evidence of clinical heterogeneity. Statistical
heterogeneity was planned to be examined with the I2 statistic and
Chi2 test. The I2 statistic describes the percentage of total varia-
tion across studies that is due to heterogeneity rather than chance.
A value of 0% indicates no observed heterogeneity; larger values
show increasing heterogeneity. Substantial heterogeneity is con-
sidered to exist when I2 is more than 50%. For the Chi2 test, a P
value of less than 0.10 was considered as indicating the presence of
statistically significant heterogeneity.We planned that if there was
any evidence of clinical or statistical heterogeneity, we would not
conduct a meta-analysis and would report findings in a narrative
form.
Assessment of reporting biases
We planned to assess reporting bias using a funnel plot.
Data synthesis
We planned to conduct a meta-analysis if the included trials were
clinically homogeneous and there was no evidence of statistical
heterogeneity. For dichotomous outcomes, we planned to use the
Mantel-Haenszel method.
Subgroup analysis and investigation of heterogeneity
If significant heterogeneity was present, and the number of studies
was sufficient, we planned to investigate heterogeneity using the
following subgroups.
1. Severity of acute traumatic brain injury (mild, moderate, or
severe).
2. Type of traumatic brain injury lesion (focal or diffuse).
3. Type of intervention (i.e. kind of haemostatic drug used).
Sensitivity analysis
We planned to perform a sensitivity analysis to investigate the
effect of the methodological quality of the included studies on the
results.
R E S U L T S
Description of studies
See: Characteristics of included studies; Characteristics of
excluded studies; Characteristics of studies awaiting classification;
Characteristics of ongoing studies.
Results of the search
The search of the databases identified a total of 659 records. These
were screened by two authors (PP and IR) and the full text of 12
potentially eligible reports were obtained for closer examination.
Of these, only two studies met the inclusion criteria. A further
study was identified by searching the reference lists of selected
seminal papers.
Included studies
Two trials were included in this systematic review. Both evaluated
the effects of recombinant factor VIIa (rFVIIa). The earlier of these
trials (Kluger 2007) was a post-hoc analysis of traumatic brain
injury (TBI) patients from a randomised controlled trial of rFVIIa
in blunt trauma patients (Boffard 2005). The later paper evaluated
the effects of rFVIIa in TBI patients with evidence of intracerebral
bleeding of at least 2ml on a baseline computed tomography (CT)
scan obtained within six hours of the injury (Narayan 2008).
More details about the studies are reported in the ’Characteristics
of included studies’ table.
Excluded studies
We identified a trial that evaluated the effects of aprotinin in pa-
tientswith severeTBI (Auer 1979). Itwas reported as a randomised
controlled trial; however after randomly allocating the first 20 pa-
tients, five patients were added to the aprotinin group. It was not
possible to separate the outcome data for the 20 randomised and
the five non-randomised patients. Therefore, this study provided
no useable outcome data and was excluded.
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Pending study results
Another trial that could contribute useful data to this systematic
review was a phase 3 randomised controlled trial that evaluated the
effect of rFVIIa in trauma patients. This trial planned to recruit
1502 patients but it was stopped by its sponsor after 550 patients
because of futility (Novoseven Study). Although we contacted the
sponsor of this trial, as of July 2009 we were not able to obtain
any data.
Ongoing studies
There are three ongoing trials that could contribute to this system-
atic review. The CRASH-2 trial (CRASH-2 Trial) is an interna-
tional study evaluating the effects of TXA in patients with trauma
and significant bleeding; a subgroup analysis of TBI patients is
planned. CRASH-2 aims to recruit 20,000 patients and will be
finished by December 2009. An explanatory study, CRASH-2
IBS (Intracranial Bleeding Study) is also being conducted among
a sample of 300 CRASH-2 participants. In patients recruited to
CRASH-2 IBS, a second CT scan is obtained within 24-48 hours
after randomisation to evaluate changes in the volume of intracra-
nial bleeding. Another trial is being conducted in Thailand to eval-
uate the effectiveness and safety of TXA for adult patients with
moderate to severe TBI. It was to recruit 240 patients and should
have been finished by May 2009 (Tranexamic acid in TBI).
Risk of bias in included studies
The review authors’ assessment of the risk of bias for each included
study can be found in Figure 1 and Figure 2.
Figure 1. Methodological quality summary: review authors’ judgements about each methodological quality
item for each included study.
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Figure 2. Methodological quality graph: review authors’ judgements about each methodological quality
item presented as percentages across all included studies. Two studies are included in this review.
Allocation
Method of allocation concealment was not reported in either of
the included studies.
Blinding
Although both studies were reported to be ’double blind’ they did
not describe the method of blinding.
Incomplete outcome data
Both studies reported the pre-specified outcomes for all included
patients. However, in the trial by Narayan and collaborators only
mortality at 15 days was reported. They also reported in-hospital
mortality after 15 days but it was not clear if this information was
collected for all the patients.
Selective reporting
A protocol was not available for either of the included studies, so
it was not possible to assess the presence of reporting bias.
Effects of interventions
We did not attempt to combine the results of the two included
trials as we judged that they included two different populations.
One study evaluated the effect of rFVIIa in trauma patients with
extracranial bleeding who also had a TBI (Kluger 2007), and the
other study only included patients with mild and moderate TBI
and evidence of traumatic intracranial bleeding in the CT scan
(Narayan 2008).
Primary outcomes
Mortality
Both studies reported on mortality.
Kluger 2007 reported a RR for mortality at 30 days of 0.64 (95%
CI 0.25 to 1.63) for patients receiving rFVIIa in comparison to
those receiving placebo.
Narayan 2008 reported a RR for mortality at the last follow-up
time of 1.08 (95% CI 0.44 to 2.68) for patients receiving rFVIIa
in comparison to those receiving placebo.
Disability
Kluger 2007 did not report the effect of rFVIIa on disability.
Narayan 2008 evaluated the effect on disability using the GOS
and the Barthex Index (BI).
The BI was evaluated in only 71 (76%) patients. The authors re-
ported that the median scores were 46.3 and 43.9 for the placebo
and rFVIIa arms, respectively. However, their report did not pro-
vide enough data (SD and denominators) to estimate the mean
difference between the twogroups. Similarly, insufficient datawere
reported to evaluate the effect on GOS. It was reported that at 15
days, 17% of the patients in the placebo and 18% in the rFVIIa
group had moderate to good recovery according to the GOS.
Thrombotic complications
Both studies reported the effect of rFVIIa on thrombotic compli-
cations.
Kluger 2007 followed the ’local diagnostic procedures’ in the case
of clinical symptoms of thromboembolic events. They reported
two serious adverse thromboembolic events in the placebo arm
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and none in the rFVIIa arm (RR 0.16, 95% CI 0.01 to 2.99 for
rFVIIa in comparison to placebo).
Narayan 2008 conducted a more intense follow up of patients to
detect thromboembolic complications. An ultrasound screening
of the lower extremities (USLE) was mandated by protocol at 72
± 8 hours to detect the presence of DVT. A 12-lead electrocar-
diogram (ECG) and a centralised laboratory measurement of tro-
ponin I were mandated at baseline and 24 hours after trial drug
administration. The authors reported that eight patients (13%)
from the rFVIIa arm presented with a thromboembolic compli-
cation, while only two patients (6%) presented with such a com-
plication in the placebo arm. The estimated RR for thrombotic
complications in this study was 2.36 (95% CI 0.53 to 10.51).
Secondary outcomes
The secondary outcomes were only reported by Narayan 2008.
Intracranial bleeding volume
Narayan 2008 analysed the effect of rFVIIa on intracranial bleed-
ing volume in different ways. For each arm, the investigators re-
ported the: 1) mean volume at baseline, 24, and 72 hours; 2)
mean volume change (defined as volume increase, no change, or
decrease) at 24 and 72 hours; and 3) volume increase at 24 and
72 hours, only considering patients in whom an increase was re-
ported. We reported the mean volume change at 72 hours as we
considered this to be both themost relevant outcome and themost
powerful analysis. The mean difference in volume change at 72
hours was -3.10 (95% CI -10.47 to 4.27) for patients receiving
rFVIIa in comparison to patients receiving placebo.
For the other secondary outcomes there were too few events to
obtain effect estimate measures.
Brain ischaemic lesions
Narayan 2008 reported one cerebral infarction in the placebo arm
and no events in the rFVIIa arm.
Need for neurosurgical operation or reoperation
Narayan 2008 reported the need for emergency intracranial bleed-
ing evacuation for three patients in the placebo group and for one
in the rFVIIa group. Two of the three placebo-treated patients who
underwent the emergency evacuation needed a reoperation, while
a reoperation was not conducted for the rFVIIa-treated patients
who underwent the emergency evacuation.
Renal failure
Neither of the studies reported on renal failure.
D I S C U S S I O N
Summary of main results
There is no reliable evidence that haemostatic drugs are effective
in reducing mortality or disability in patients with TBI. Only two
studies evaluating the effects of rFVIIa were found. One of them
was a post-hoc analysis of a trial including 30 bleeding trauma
patients with a concomitant moderate or mild TBI. This result
should be considered with caution as it was a post-hoc analysis of
a subgroup of patients (with TBI) within a larger trial of trauma
patients. Posteriori subgroup analyses are likely to be misleading as
they can be the result of data dredging and chance. The other study
included 97 TBI patients with evidence of intracerebral bleeding
in the initial CT scan.
Both studies were too small to confirm or refute a clinically plau-
sible effect in the TBI population. We did not find a single ran-
domised controlled trial of an antifibrinolytic drug for TBI pa-
tients. The pending results of the Novoseven study and the results
of the ongoing studies with tranexamic acid (TXA) will provide
useful information about the effects of haemostatic drugs in TBI
patients.
Quality of the evidence
Neither of the trial reports provided enough data to assess the risk
of bias for sequence generation, allocation concealment, blinding,
or selective reporting.
Potential biases in the review process
Although our search was comprehensive and we used validated
search strategies, the possibility of publication bias cannot be ruled
out. Because few studies were included in this review we were not
able to conduct formal analysis of publication bias (a funnel plot).
Full protocols of the included studies were not available so we
couldnot assess the presence of selective reporting bias, however for
our primary outcome (mortality) this type of bias is very unlikely.
Finally, one of the included trials was a post-hoc subgroup analysis
and its result should be considered with caution.
Agreements and disagreements with other
studies or reviews
This is the first review to evaluate the effects of haemostatic drugs
in TBI patients. However, other reviews related to this question
have been published.
Stanworth and collaborators conducted a systematic review on
rFVIIa for the prevention and treatment of bleeding in patients
without haemophilia (Stanworth 2007). This review included the
randomised controlled trial in trauma patients from which the
post-hoc analysis reported in our systematic review was conducted
(Boffard 2005). However, that review did not analyse the effect of
rFVIIa in TBI patients.
Another Cochrane review evaluated the effects of antifibrinolytic
agents in trauma patients (Coats 2004). That review included two
studies, one of them (Auer 1979) is among the excluded studies for
our review. The trial involved TBI patients and the intervention
under study was aprotinin, but the report provided no useable
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outcome data. The other study reported in the review by Coats
and collaborators did not include TBI patients.
A recent review of the clinical use of rFVIIa evaluated the effects
of rFVIIa in different conditions usually treated in the emergency
department (Fishman 2008). Among the outcomes, the effect
on trauma patients was reported although TBI patients were not
specifically included. The only included randomised controlled
trial involving trauma patients was by Boffard 2005, which is in-
cluded in this systematic review.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
There is no reliable evidence to recommend the use of haemostatic
drugs for TBI patients.
Implications for research
New randomised clinical trials assessing the effects of haemostatic
drugs in TBI patients should be conducted. These trials should be
large enough to detect clinically plausible effects.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Kluger 2007
Methods Randomised clinical trial.
Participants 30 adult patients (between 16 and 65 years old) with severe blunt trauma and moderate
or mild traumatic brain injury (based on CT scan results)
Exclusion criteria were: cardiac arrest pre-hospital or in the emergency or operating room,
prior to trial drug administration; gunshot wound to the head; base deficit of greater
than 15 mEq/l or severe acidosis with pH of less than 7.00; transfusion of 8 or more
units of RBCs prior to arrival at the trauma center; injury sustained greater than or equal
to 12 hours before randomisation; and severe TBI, defined as a Glasgow Coma Scale
(GCS) score of less than or equal to 8, unless in the presence of a normal head CT scan
Interventions Eligible patients were randomly assigned to treatment groups within a 4-hour period.
Treatment armswere either three intravenous injections of rFVIIa (200, 100, and100µg/
kg) or three placebo injections. The first dose of study drugwas administered immediately
after transfusion of the eighth unit of RBCs. The second and third doses followed 1 and
3 hours after the first dose, respectively
Outcomes Mortality was categorised as: early (<48 hours) or late (between 48 hours and 30 days)
Notes This study was a post hoc analysis of patients with traumatic brain injury enrolled into
a randomised, placebo-controlled study of patients with severe blunt trauma
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Not described.
Allocation concealment? Unclear Not described.
Blinding?
All outcomes
Unclear Reported as “double blind” but method of blinding was not
reported
Incomplete outcome data addressed?
All outcomes
Yes Outcome reported for all included patients.
Free of selective reporting? Unclear The protocol is not available.
Free of other bias? Unclear -
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Narayan 2008
Methods Randomised clinical trial.
Participants 97 adult patients (>18 years old) with traumatic brain injury, a Glasgow Coma Scale
(GCS) score between 4 and 14, and evidence of traumatic intracerebral bleeding with
a total volume of at least 2 ml on the baseline CT scan obtained within 6 hours of the
injury
Exclusion criteria were: the presence of penetrating head or spinal cord injury; life ex-
pectancy of less than 24 hours after hospital admission; any planned surgical evacua-
tion of intracerebral haematoma within 24 hours after dosing; isolated subarachnoid
haemorrhage, intraventricular haemorrhage, epidural or subdural haematomas or sICH;
significant cardiovascular disease or dysfunction; haemodynamic instability; known his-
tory of hypercoagulability or thromboembolism; current vitamin K antagonist use; and
pregnancy
Interventions Five doses of rFVIIa (40, 80, 120, 160, and 200 µg/kg) were compared with placebo
in escalating dose tiers. The first dose tier (40 µg/kg) was assigned in a 1:1 ratio to the
treatment or placebo group. Subsequent dose tiers were assigned in a 2:1 ratio
Outcomes The primary objective of this study was to evaluate safety of the intervention. All adverse
events, defined as deep vein thrombosis (DVT), pulmonary embolism (PE), myocardial
infarction, cerebral infarction, disseminated intravascular coagulation or coagulopathy
were reported until day 15
Early mortality was defined as within 15 days of recruitment, and late mortality as any
death after 15 days of recruitment
The effectiveness assessment focused on changes in haematoma volumes on CT scans
between baseline, 24 hours, and 72 hours after the intervention
Notes
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Not described.
Allocation concealment? Unclear Not described.
Blinding?
All outcomes
Unclear Reported as “double blind” but method of blinding was not
reported
Incomplete outcome data addressed?
All outcomes
Yes Outcome reported for all the patients included. The only
exception was late mortality (more than 15 days) for which
the authors stated that they did not record it systemati-
cally for all the patients but recorded only those in-hospital
deaths reported by collaborators
Free of selective reporting? Unclear Protocol not available.
Free of other bias? Unclear -
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Auer 1979 This study is described as a randomised controlled trial of aprotinin versus placebo in patients with severe traumatic
brain injury but, after randomly allocating the first 20 patients, five patients were added to the aprotinin group. Because
it was not possible to separate the outcome data for the 20 randomised and the five non-randomised patients, this study
provided no useable outcome data
Characteristics of studies awaiting assessment [ordered by study ID]
Novoseven Study
Methods Randomised controlled trial.
Participants 550 severely injured trauma patients with bleeding refractory to standard treatment
Interventions Three single doses of rFVIIa (200 µg/kg + 100 µg/kg + 100 µg/kg) or placebo
Outcomes Mortality at 30 days.
Notes This study planned to recruit 1502 patients but after recruiting 550 patients, in June 2008 the sponsor (Novo
Nordisk) made the announcement that they were stopping this trial as it was futile. Some of the patients recruited
in this trial had traumatic brain injury and could provide useful data for this systematic review. We contacted Novo
Nordisk but we were unable to obtain any data
Characteristics of ongoing studies [ordered by study ID]
CRASH-2 Trial
Trial name or title CRASH-2.
Methods Randomised clinical trial.
Participants Adults with trauma who are within 8 hours of injury and have either significant haemorrhage or are considered
to be at risk of significant haemorrhage. The trial will recruit 20,000 patients and is planned to finish in
December 2009
Interventions 2 g of tranexamic acid or placebo.
Outcomes Primary outcome: death in hospital within four weeks of injury
Secondary outcome: receipt of a blood product transfusion, the number of units of blood products transfused,
surgical intervention, and the occurrence of thromboembolic episodes
Starting date May 2005
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CRASH-2 Trial (Continued)
Contact information CRASH@lshtm.ac.uk
Notes
Tranexamic acid in TBI
Trial name or title Tranexamic Acid for Preventing Progressive Intracranial Haemorrhage in Traumatic Brain Injury
Methods Randomised clinical trial.
Participants Adult patients with moderate or severe TBI.
Interventions 2 g of tranexamic acid or placebo.
Outcomes Primary outcome: progressive intracranial haemorrhage at 24 ± 8 hours confirmed by repeated CT of the
brain
Secondary outcome: functional scale (GOS, DRS), mortality, operative treatment (later surgery for bleeding)
, adverse effect and transfusion needed
Starting date October 2008
Contact information surakrant@gmail.com
Notes
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D A T A A N D A N A L Y S E S
Comparison 1. Outcomes
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mortality 2 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
2 Thrombotic complication 2 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
3 Change in volume of intracranial
bleeding
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
Analysis 1.1. Comparison 1 Outcomes, Outcome 1 Mortality.
Review: Haemostatic drugs for traumatic brain injury
Comparison: 1 Outcomes
Outcome: 1 Mortality
Study or subgroup Factor VIIa Control Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Kluger 2007 5/17 6/13 0.64 [ 0.25, 1.63 ]
Narayan 2008 11/61 6/36 1.08 [ 0.44, 2.68 ]
0.01 0.1 1 10 100
Favours Factor VIIa Favours control
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Analysis 1.2. Comparison 1 Outcomes, Outcome 2 Thrombotic complication.
Review: Haemostatic drugs for traumatic brain injury
Comparison: 1 Outcomes
Outcome: 2 Thrombotic complication
Study or subgroup Factor VIIa Control Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Kluger 2007 0/17 2/13 0.16 [ 0.01, 2.99 ]
Narayan 2008 8/61 2/36 2.36 [ 0.53, 10.51 ]
0.01 0.1 1 10 100
Favours Factor VIIa Favours control
Analysis 1.3. Comparison 1 Outcomes, Outcome 3 Change in volume of intracranial bleeding.
Review: Haemostatic drugs for traumatic brain injury
Comparison: 1 Outcomes
Outcome: 3 Change in volume of intracranial bleeding
Study or subgroup Factor VIIa Control
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Narayan 2008 60 4.1 (10) 35 7.2 (20.9) -3.10 [ -10.47, 4.27 ]
-100 -50 0 50 100
Favours Factor VIIa Favours control
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A P P E N D I C E S
Appendix 1. Search strategy
Cochrane Injuries Group Specialised Register (searched 3 February 2009)
1. ((haemosta* or hemosta* or antihaemorrhag* or antihemorrhag*) and (drug* or agent* or treat* or therap*)) or ((coagulat* or
clotting) and (factor*)) or (“Tranexamic Acid” or Antithrombins* or anti-fibrinolytic* or antifibrinolytic* or antifibrinolysin* or anti-
fibrinolysin* or antiplasmin* or anti-plasmin* or “plasmin inhibitors” or “thrombin inhibitors” or “factor 7a” or “factor VIIa” or factor
IXa)
2. ((head or crani* or cerebr* or capitis or brain* or forebrain* or skull* or hemispher* or intra-cran* or inter-cran*) and (injur* or
trauma* or damag* or wound* or fracture* or contusion*)) or ((head or crani* or cerebr* or brain* or intra-cran* or inter-cran*) and
(haematoma* or hematoma* or haemorrhag* or hemorrhag* or bleed* or pressure)) or ((brain or cerebral or intracranial) and (oedema
or edema or swell*)) or ((unconscious* or coma* or concuss* or ’persistent vegetative state’) and (injur* or trauma* or damag* or wound*
or fracture*)) or (“Glasgow coma score”) or (“Glasgow outcome score”) or (“Glasgow coma scale”) or (“Glasgow outcome scale”) or
(“diffuse axonal injury” or “diffuse axonal injuries”)
3. 1 and 2
CENTRAL (The Cochrane Library 2009, Issue 1)
#1 MeSH descriptor Craniocerebral Trauma explode all trees
#2 MeSH descriptor Cerebrovascular Trauma explode all trees
#3 MeSH descriptor Brain Edema explode all trees
#4 (brain or cerebral or intracranial) next (oedema or edema or swell*)
#5 MeSH descriptor Glasgow Coma Scale explode all trees
#6 MeSH descriptor Glasgow Outcome Scale explode all trees
#7 MeSH descriptor Unconsciousness explode all trees
#8 glasgow next (coma or outcome) next (score or scale)
#9 (Unconscious* or coma* or concuss* or ’persistent vegetative state’) near5 (injur* or trauma* or damag* or wound* or fracture*)
#10 “Rancho Los Amigos Scale”
#11 (head or crani* or cerebr* or capitis or brain* or forebrain* or skull* or hemispher* or intra-cran* or inter-cran*) near3 (injur* or
trauma* or damag* or wound* or fracture* or contusion*)
#12 Diffuse next axonal next injur*
#13 (head or crani* or cerebr* or brain* or intra-cran* or inter-cran*) near3 (haematoma* or hematoma* or haemorrhag* or hemorrhag*
or bleed* or pressure)
#14 (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13)
#15 MeSH descriptor Hemostatics explode all trees
#16 MeSH descriptor Blood Coagulation Factors explode all trees
#17 MeSH descriptor Hemostasis explode all trees with qualifier: DE
#18 MeSH descriptor Blood Coagulation explode all trees with qualifier: DE
#19 MeSH descriptor Fibrinolysis explode all trees with qualifier: DE
#20 MeSH descriptor Platelet Activation explode all trees with qualifier: DE
#21 MeSH descriptor Antithrombins explode all trees with qualifier: DE
#22 MeSH descriptor Thrombin explode all trees with qualifier: DE
#23 (haemosta* or hemosta* or antihaemorrhag* or antihemorrhag*) near5 (drug* or agent* or treat* or therap*):ab,ti
#24 (coagulat* or clotting) next (factor*):ab,ti
#25 MeSH descriptor Factor VIIa explode all trees
#26 (factor) next (7a or VIIa or VII):ab,ti
#27 MeSH descriptor Factor IXa explode all trees
#28 MeSH descriptor Estrogens, Conjugated (USP) explode all trees
#29 (conjugated next estrogen*) or (carentil or congest or dagynil or oestrofeminal or estro-feminal or oestro-feminal or prelestrin or
premarin or climarest or climopax or presomen or progens or transannon or femavit):ab,ti
#30 MeSH descriptor Erythropoietin explode all trees
#31 MeSH descriptor Erythropoietin, Recombinant explode all trees
#32 erythropoietin or recormon or epoetin alfa or epogen or eprex:ti,ab
#33 MeSH descriptor Deamino Arginine Vasopressin explode all trees
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#34 (deamino next arginine) or (desmopressin or adiuretin or apo-desmopressin or ddavp or desmopressine or desmospray or desmotabs
or octim or octostim or minirin or minurin or desmogalen or nocutil or stimate or Arginine or Vasopressins or DDVAP):ti
#35 MeSH descriptor Antifibrinolytic Agents explode all trees
#36 MeSH descriptor Aprotinin explode all trees
#37 MeSH descriptor Aminocaproic Acids explode all trees
#38 MeSH descriptor Tranexamic Acid explode all trees
#39 (aminocaproic or 6-aminohexanoic or epsilon-aminocaproic) next (acid*):ti
#40 (tranexamic acid or TXA or amcha or amca or cyklokapron or kabi-2161 or transamin or ugurol or t-amcha or trans-4-aminomethyl-
cyclohexanecarboxylic acid or EACA):ab,ti
#41 (amicar or caprocid or epsamon or epsikapron or aprotinin* or BPTI or antilysin or contrical or contrykal or dilmintal or iniprol
or kontrikal or kontrykal or pulmin or trasylol or zymofren or argatroban):ab,ti
#42 (Basic or bovine or kunitz or kallikrein) next (trypsin inhibitor* or trypsin inactivator*):ab,ti
#43 (kallikrein-trypsin or bovine pancreatic trypsin or tranexamic or cyklokapron or pharmacia or t-amcha or amcha or ugurol or
transamin or kabi or epsilon-aminocaproic acid or aminocaproic or lederle):ab,ti
#44 (anti-fibrinolytic* or antifibrinolytic* or antifibrinolysin* or anti-fibrinolysin* or antiplasmin* or anti-plasmin*) or (plasmin next
inhibitor*) or (thrombin next inhibitor*):ab,ti
#45 (#15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24 OR #25 OR #26 OR #27 OR #28 OR #29
OR #30 OR #31 OR #32 OR #33 OR #34 OR #35 OR #36 OR #37 OR #38 OR #39 OR #40 OR #41 OR #42 OR #43 OR #44)
#46 (#14 AND #45)
MEDLINE (Ovid SP) 1950 to week 3 January 2009
1. exp Craniocerebral Trauma/
2. exp Brain Edema/
3. exp Glasgow Coma Scale/
4. exp Glasgow Outcome Scale/
5. exp Unconsciousness/
6. exp Cerebrovascular Trauma/
7. ((head or crani* or cerebr* or capitis or brain* or forebrain* or skull* or hemispher* or intra-cran* or inter-cran*) adj3 (injur* or
trauma* or damag* or wound* or fracture* or contusion*)).ab,ti.
8. ((head or crani* or cerebr* or brain* or intra-cran* or inter-cran*) adj3 (haematoma* or hematoma* or haemorrhag* or hemorrhag*
or bleed* or pressure)).ti,ab.
9. (Glasgow adj (coma or outcome) adj (scale* or score*)).ab,ti.
10. “rancho los amigos scale”.ti,ab.
11. (“diffuse axonal injury” or “diffuse axonal injuries”).ti,ab.
12. ((brain or cerebral or intracranial) adj (oedema or edema or swell*)).ab,ti.
13. ((unconscious* or coma* or concuss* or ’persistent vegetative state’) adj5 (injur* or trauma* or damag* or wound* or fracture*)).ti,ab.
14. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13
15. exp hemostatics/
16. exp blood coagulation factors/
17. hemostasis/de or blood coagulation/de or fibrinolysis/de or exp platelet activation/de or exp antithrombins/ or thrombin/ai
18. ((h?emosta* or antih?emorrhag*) adj5 (drug* or agent* or treat* or therap*)).ab,ti.
19. ((coagulat* or clotting) adj factor*).ab,ti.
20. exp Factor VIIa/
21. (factor adj (7a or VIIa or VII)).ab,ti.
22. exp factor ixa/
23. exp “Estrogens, Conjugated (USP)”/
24. ((conjugated adj3 estrogen*) or carentil or congest or dagynil or oestrofeminal or estro-feminal or oestro-feminal or prelestrin or
premarin or climarest or climopax or presomen or progens or transannon or femavit).ab,ti.
25. exp Erythropoietin/ or exp Erythropoietin, Recombinant/ or exp Receptors, Erythropoietin/
26. (erythropoietin or recormon or epoetin alfa or epogen or eprex).ti,ab.
27. exp Deamino Arginine Vasopressin/
28. ((deamino adj arginine) or desmopressin or adiuretin or apo-desmopressin or ddavp or desmopressine or desmospray or desmotabs
or octim or octostim or minirin or minurin or desmogalen or nocutil or stimate or Arginine or Vasopressins or DDVAP).ti.
29. exp Antifibrinolytic Agents/
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30. exp Aprotinin/
31. exp Aminocaproic Acids/
32. exp Tranexamic Acid/
33. ((aminocaproic or 6-aminohexanoic or epsilon-aminocaproic) adj acid*).ti,ab.
34. (tranexamic acid or TXA or amcha or amca or cyklokapron or kabi-2161 or transamin or ugurol or t-amcha or trans-4-aminomethyl-
cyclohexanecarboxylic acid or EACA).ab,ti.
35. (amicar or caprocid or epsamon or epsikapron or aprotinin* or BPTI or antilysin or contrical or contrykal or dilmintal or iniprol
or kontrikal or kontrykal or pulmin or trasylol or zymofren or argatroban).ab,ti.
36. ((Basic or bovine or kunitz or kallikrein) adj (trypsin inhibitor* or trypsin inactivator*)).ab,ti.
37. (kallikrein-trypsin or bovine pancreatic trypsin or tranexamic or cyklokapron or pharmacia or t-amcha or amcha or ugurol or
transamin or kabi or epsilon-aminocaproic acid or aminocaproic or lederle).ab,ti.
38. (anti-fibrinolytic* or antifibrinolytic* or antifibrinolysin* or anti-fibrinolysin* or antiplasmin* or anti-plasmin* or (plasmin adj
inhibitor*) or (thrombin adj inhibitor*)).ab,ti.
39. 15 or 16 or 17 or 18 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37
or 38
40. 14 and 39
41. randomi?ed.ab,ti.
42. randomized controlled trial.pt.
43. controlled clinical trial.pt.
44. placebo.ab.
45. clinical trials as topic.sh.
46. randomly.ab.
47. trial.ti.
48. 41 or 42 or 43 or 44 or 45 or 46 or 47
49. (animals not (humans and animals)).sh.
50. 48 not 49
51. 40 and 50
PubMed (www.ncbi.nlm.nih.gov/sites/entrez/) (searched 3 Feb 2009: added to PubMed in the last 180 days)
#1((haemosta* or hemosta* or antihaemorrhag* or antihemorrhag*) and (drug or drugs or agent* or treatment* or therapy or therapies
or therapeutic*)) or ((coagulat* or clotting) and (factor or factors)) or (“Tranexamic Acid” or Antithrombins* or anti-fibrinolytic*
or antifibrinolytic* or antifibrinolysin* or anti-fibrinolysin* or antiplasmin* or anti-plasmin* or “plasmin inhibitors” or “thrombin
inhibitors” or “factor 7a” or “factor VIIa” or factor IXa)
#2((head or craniu* or crania* or cerebra* or cerebru* or capitis or brain* or forebrain* or skull* or hemispher* or intra-cran* or
inter-cran*) and (injury or injuries or trauma or traumas or traumatic or damag* or wound* or fracture* or contusion*)) or ((head or
craniu* or crania* or cerebra* or cerebru* or brain* or intra-cran* or inter-cran*) and (haematoma* or hematoma* or haemorrhag* or
hemorrhag* or bleed* or pressure)) or ((brain or cerebral or intracranial) and (oedema or edema or swell*)) or ((unconscious* or coma*
or concuss* or ’persistent vegetative state’) and (injury or injuries or trauma or traumas or traumatic or damag* or wound* or fracture*))
or (“Glasgow coma score”) or (“Glasgow outcome score”) or (“Glasgow coma scale”) or (“Glasgow outcome scale”) or (“diffuse axonal
injury” or “diffuse axonal injuries”)
#3((randomized controlled trial[pt] OR controlled clinical trial[pt]) OR (randomized OR randomised OR randomly ORplacebo[tiab])
OR (trial[ti]) OR (“Clinical Trials as Topic”[MeSH Major Topic])) NOT ((“Animals”[Mesh]) NOT (“Humans”[Mesh] AND “Ani-
mals”[Mesh]))
#4#1 and #2 and #3
EMBASE (Ovid SP) 1980 to week 4 January 2009
1.exp Brain Injury/
2.exp Brain Edema/
3.exp Glasgow Coma Scale/
4.exp Glasgow Outcome Scale/
5.exp Rancho Los Amigos Scale/
6.exp Unconsciousness/
7.((brain or cerebral or intracranial) adj5 (oedema or edema or swell$)).ab,ti.
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8.((head or crani$ or cerebr$ or capitis or brain$ or forebrain$ or skull$ or hemispher$ or intra-cran$ or inter-cran$) adj5 (injur$ or
trauma$ or damag$ or wound$ or fracture$ or contusion$)).ab,ti.
9.(Glasgow adj (coma or outcome) adj (scale$ or score$)).ab,ti.
10.Rancho Los Amigos Scale.ab,ti.
11.((unconscious$ or coma$ or concuss$ or ’persistent vegetative state’) adj3 (injur$ or trauma$ or damag$ or wound$ or frac-
ture$)).ti,ab.
12.Diffuse axonal injur$.ab,ti.
13.((head or crani$ or cerebr$ or brain$ or intra-cran$ or inter-cran$) adj3 (haematoma$ or hematoma$ or haemorrhag$ or hemorrhag$
or bleed$ or pressure)).ab,ti.
14.or/1-13
15.exp Randomized Controlled Trial/
16.exp controlled clinical trial/
17.randomi?ed.ab,ti.
18.placebo.ab.
19.*Clinical Trial/
20.randomly.ab.
21.trial.ti.
22.15 or 16 or 17 or 18 or 19 or 20 or 21
23.exp animal/ not (exp human/ and exp animal/)
24.22 not 23
25.14 and 24
26.exp Hemostatic Agent/
27.exp Blood Clotting Factor/
28.hemostasis/de or blood coagulation/de or fibrinolysis/de or exp platelet activation/de or exp antithrombins/ or thrombin/ai
29.((h?emosta* or antih?emorrhag*) adj5 (drug* or agent* or treat* or therap*)).ab,ti.
30.((coagulat* or clotting) adj factor*).ab,ti.
31.exp Blood Clotting Factor 7a/
32.(factor adj (7a or VIIa or VII)).ab,ti.
33.exp Blood Clotting Factor 9a/
34.exp “Estrogens, Conjugated (USP)”/
35.((conjugated adj3 estrogen*) or carentil or congest or dagynil or oestrofeminal or estro-feminal or oestro-feminal or prelestrin or
premarin or climarest or climopax or presomen or progens or transannon or femavit).ab,ti.
36.exp Erythropoietin/ or exp Recombinant Erythropoietin/ or exp Erythropoietin Receptor/
37.(erythropoietin or recormon or epoetin alfa or epogen or eprex).ti,ab.
38.exp “Argipressin[1 Deamino]”/
39.((deamino adj arginine) or desmopressin or adiuretin or apo-desmopressin or ddavp or desmopressine or desmospray or desmotabs
or octim or octostim or minirin or minurin or desmogalen or nocutil or stimate or Arginine or Vasopressins or DDVAP).ti.
40.exp Antifibrinolytic Agent/
41.exp Aprotinin/
42.exp Aminocaproic Acid/ or exp Aminocaproic Acid Derivative/
43.exp Tranexamic Acid/
44.((aminocaproic or 6-aminohexanoic or epsilon-aminocaproic) adj acid*).ti,ab.
45.(tranexamic acid or TXA or amcha or amca or cyklokapron or kabi-2161 or transamin or ugurol or t-amcha or trans-4-aminomethyl-
cyclohexanecarboxylic acid or EACA).ab,ti.
46.(amicar or caprocid or epsamon or epsikapron or aprotinin* or BPTI or antilysin or contrical or contrykal or dilmintal or iniprol
or kontrikal or kontrykal or pulmin or trasylol or zymofren or argatroban).ab,ti.
47.((Basic or bovine or kunitz or kallikrein) adj (trypsin inhibitor* or trypsin inactivator*)).ab,ti.
48.(kallikrein-trypsin or bovine pancreatic trypsin or tranexamic or cyklokapron or pharmacia or t-amcha or amcha or ugurol or
transamin or kabi or epsilon-aminocaproic acid or aminocaproic or lederle).ab,ti.
49.(anti-fibrinolytic* or antifibrinolytic* or antifibrinolysin* or anti-fibrinolysin* or antiplasmin* or anti-plasmin* or (plasmin adj
inhibitor*) or (thrombin adj inhibitor*)).ab,ti.
50.or/26-49
51.25 and 50
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CINAHL (EBSCO) 1982 to January 2009
1.S35 (S24 and S34)
2.S34 (S25 or S26 or S27 or S28 or S29 or S30 or S31 or S32 or S33)
3.S33 TI ( anti-fibrinolytic* or antifibrinolytic* or antifibrinolysin* or
4.anti-fibrinolysin* or antiplasmin* or anti-plasmin* ) or TI plasmin
5.inhibitor* or TI thrombin inhibitor*
6.S32 AB ( anti-fibrinolytic* or antifibrinolytic* or antifibrinolysin* or
7.anti-fibrinolysin* or antiplasmin* or anti-plasmin* ) or AB plasmin
8.inhibitor* or AB thrombin inhibitor*
9.S31 AB ( coagulat* or clotting ) and AB factor*
10.S30 TI ( coagulat* or clotting ) and TI factor*
11.S29 TI ( haemosta* or hemosta* or antihaemorrhag* or antihemorrhag* ) and
12.TI ( drug* or agent* or treat* or therap* )
13.S28 AB ( haemosta* or hemosta* or antihaemorrhag* or antihemorrhag* ) and
14.AB ( drug* or agent* or treat* or therap* )
15.S27 (MH “Blood Coagulation+”)
16.S26 (MH “Blood Coagulation Factors+”)
17.S25 (MH “Hemostatics+”) or (MH “Hemostatic Techniques+”)
18.S24 (S11 and S23)
19.S23 (S12 or S13 or S14 or S15 or S16 or S17 or S18 or S19 or S20 or S21 or
20.S22)
21.S22 AB singl* W3 blind* or AB doubl* W3 blind* or AB trebl* W3 blind* or
22.AB tripl* W3 blind*
23.S21 TI singl* W3 blind* or TI doubl* W3 blind* or TI trebl* W3 blind* or
24.TI tripl* W3 blind*
25.S20 MH quantitative studies
26.S19 TX random* N3 allocat*
27.S18 MH random assignment
28.S17 TX placebo*
29.S16 MH placebos
30.S15 TX randomi?ed N3 control* N3 trial*
31.S14 TX clinical N3 trial*
32.S13 PT clinical trial*
33.S12 MH clinical trials
34.S11 S1 or S2 or S3 or S4 or S5 or S6 or S7 or S8 or S9 or S10
35.S10 TI ( head or crani* or cerebr* or brain* or intra-cran* or inter-cran*
36.) and AB ( haematoma* or hematoma* or haemorrhag* or hemorrhag* or bleed*
37.or pressure )
38.S9 AB ( head or crani* or cerebr* or capitis or brain* or forebrain* or
39.skull* or hemispher* or intra-cran* or inter-cran* ) and TI ( injur* or
40.trauma* or damag* or wound* or fracture* or contusion* )
41.S8 TX Diffuse W1 axonal N3 injur*
42.S7 TX Rancho Los Amigos Scale
43.S6 AB ( Unconscious* or coma* or concuss* or “persistent vegetative state”
44.) and TI ( injur* or trauma* or damag* or wound* or fracture* )
45.S5 TX glasgow and TX ( coma or outcome ) and TX ( score or scale )
46.S4 (MH “Unconsciousness+”) or (MH “Brain Concussion+”)
47.S3 (MH “Glasgow Coma Scale”)
48.S2 (MH “Brain Injuries+”)
49.S1 (MH “Head Injuries+”)
ISI Web of Science: Science Citation Index Expanded (SCI-EXPANDED) (1970 to January 2009) and Conference Proceedings
Citation Index- Science (CPCI-S) (1990 to January 2009)
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1.Topic=((haemosta* or hemosta* or antihaemorrhag* or antihemorrhag*) SAME (drug* or agent* or treat* or therap*)) OR Topic=
((coagulat* or clotting) SAME (factor*)) OR Topic=((factor) SAME (7a or VIIa or VII OR IX)) OR Topic=((conjugated) SAME
(estrogen* OR oestrogen*))
2.Topic=(carentil or congest or dagynil or oestrofeminal or estro-feminal or oestro-feminal or prelestrin or premarin or climarest or
climopax or presomen or progens or transannon or femavit) OR Topic=(erythropoietin or recormon or epoetin alfa or epogen or eprex)
AND Topic=(desmopressin or adiuretin or apo-desmopressin or ddavp or desmopressine or desmospray or desmotabs or octim or
octostim or minirin or minurin or desmogalen or nocutil or stimate or Arginine or Vasopressins or DDVAP) AND Topic=(deamino
SAME arginine)
3.Topic=(amicar or caprocid or epsamon or epsikapron or aprotinin* or BPTI or antilysin or contrical or contrykal or dilmintal or
iniprol or kontrikal or kontrykal or pulmin or trasylol or zymofren or argatroban OR Aminocaproic Acid* OR Tranexamic Acid*)
OR Topic=(anti-fibrinolytic* or antifibrinolytic* or antifibrinolysin* or anti-fibrinolysin* or antiplasmin* or anti-plasmin*) OR Topic=
(plasmin SAME inhibitor*) OR Topic=(thrombin SAME inhibitor*)
4.Topic=(kallikrein-trypsin or bovine pancreatic trypsin or tranexamic or cyklokapron or pharmacia or t-amcha or amcha or ugurol or
transamin or kabi or epsilon-aminocaproic acid or aminocaproic or lederle) OR Topic=((Basic or bovine or kunitz or kallikrein) SAME
(trypsin inhibitor* or trypsin inactivator*))
5.1 or 2 or 3 or 4
6.Topic=(glasgow SAME (coma or outcome) SAME (score or scale)) OR Topic=((Unconscious* or coma* or concuss* or ’persistent
vegetative state’) SAME (injur* or trauma* or damag* or wound* or fracture*)) OR Topic=(“Rancho Los Amigos Scale” OR diffuse
axonal injur*) OR Topic=((head or crani* or cerebr* or capitis or brain* or forebrain* or skull* or hemispher* or intra-cran* or inter-
cran*) same (injur* or trauma* or damag* or wound* or fracture* or contusion*)) OR Topic=((head or crani* or cerebr* or brain* or
intra-cran* or inter-cran*) SAME (haematoma* or hematoma* or haemorrhag* or hemorrhag* or bleed* or pressure))
7.TS=((injur* or trauma* or lesion* or damage* or wound* or oedema* or edema* or fracture* or contusion* or concus* or commotion*
or pressur*) SAME (head or crani* or capitis or brain* or forebrain* or skull* or hemisphere or intracran* or orbit*)) OR TS=
(Craniocerebral Trauma OR Cerebrovascular Trauma OR Brain Edema) OR TS=((brain or cerebral or intracranial) SAME (oedema
or edema or swell*))
8.6 or 7
9.Topic=((singl* OR doubl* OR trebl* OR tripl*) SAME (blind* OR mask*))
10.Topic=(randomised OR randomized OR randomly OR random order OR random sequence OR random allocation OR randomly
allocated OR at random OR randomized controlled trial) OR Topic=(controlled clinical trial OR controlled trial OR clinical trial OR
placebo)
11. 9 or 10
12. 5 and 8 and 11
H I S T O R Y
Protocol first published: Issue 3, 2009
Review first published: Issue 1, 2010
C O N T R I B U T I O N S O F A U T H O R S
PP and IR developed the search strategy, scanned the search results, extracted the data and drafted the first version of the review. SY
drafted the first version of the protocol, which provides the foundation of the review.
All the authors edited and approved the review.
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D E C L A R A T I O N S O F I N T E R E S T
None known.
S O U R C E S O F S U P P O R T
Internal sources
• Thai Cochrane Network, Thailand.
• Faculty of Medicine, Khon Kaen University, Thailand.
• Khon Kaen Hospital, Ministry of Public Health, Thailand.
• Cochrane Injuries Group, UK.
• London School of Hygiene & Tropical Medicine, UK.
External sources
• The Thailand Research Fund, Senior Research Scholar, Thailand.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
We removed desmopressin, oestrogens, and activated factor IX from the interventions, and we focused on the most commonly used
haemostatic drugs (antifibrinolytics, and rFVIIa).
I N D E X T E R M S
Medical Subject Headings (MeSH)
Cerebral Hemorrhage, Traumatic [∗drug therapy]; Factor VIIa [∗therapeutic use]; Head Injuries, Closed [∗complications]; Hemostatics
[∗therapeutic use]; Randomized Controlled Trials as Topic; Recombinant Proteins [therapeutic use]
MeSH check words
Humans
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